Home
Agenda
Sponsors
Speakers
FAQs
Login
Back To Speakers

Sean Delaney

Alberta Transplant Insititute, Patient Partner & Research and Education Program Manager

Sean Delaney is based in Edmonton, Alberta and has worked as a senior health policy and management professional in the OTDT ecosystem for the past 20 years. His career spans work in hospitals, health regions, provincial government and nationally with Canadian Blood Services for 16 years. Most recently, Sean has joined the Alberta Transplant Institute (ATI) as a leader where he supports researchers and decision makers in driving innovation in Alberta to benefit the care for patients, families/caregivers, and donors. He is also a lifelong kidney patient and 2-time kidney transplant recipient, receiving his most recent transplant from a generous living donor in October 2020.

Taking a part in
Thu, Dec 07
1:00 PM - 2:00 PM EST

The future application of designer cells and bioengineered tissues in clinical settings holds immense promise for revolutionizing regenerative medicine and transplantation, yet it also confronts significant feasibility challenges. The ability to precisely tailor cells and tissues for therapeutic purposes can have significant impact in transplantation opening avenues for personalized medicine and access to ‘off-the-shelf’ tissues and organs. However, the translation of these cutting-edge technologies from the laboratory to clinical practice requires overcoming formidable hurdles, including safety concerns, ethical considerations, community acceptance and the need for robust regulatory frameworks. Technical challenges such as the scalability and cost-effectiveness of producing designer cells and tissues also present major logistical challenges. As research continues to push the boundaries of synthetic biology and tissue engineering, the ultimate success and integration of designer cells and bioengineered tissues in the medical landscape will require close collaboration from scientists, clinicians, and policymakers; and importantly communication with patient communities, some of whom, will be future recipients of these new therapeutic modalities.

This session is supported by the Canadian Institutes of Health Research (CIHR).

Session Chairs: 

  • Dr. Golnaz Karoubi (Senior Chair) – University Health Network, University of Toronto
  • Ms. Aisha Adil (Junior Chair) – University Health Network, University of Toronto

Panelists:

  • Dr. Siba Haykal - University Health Network/University of Toronto
  • Dr. Ian Rogers – Sinai Health Systems/University of Toronto
  • Dr. Braulio Marfil-Garza – University of Alberta
  • Mr. Sean Delaney – University of Alberta

Speakers: Siba Haykal, Golnaz Karoubi, Aisha Adil, Braulio Marfil-Garza, Sean Delaney, Ian Rogers

 
Reset

Filters

Tracks
Item
Item
Item
Item
Types
Item
Item
Item
Item
Speakers
Item
Item
Item
Item
Spaces
Item
Item
Item
Item